Tumor necrosis factor receptor-associated factor–CD30 interaction (TRAF–CD30 interaction)

The Tumor necrosis factor receptor-associated factor (TRAF)–CD30 interaction is a critical signaling node within the tumor necrosis factor receptor superfamily (TNFRSF). CD30 (TNFRSF8) is a transmembrane glycoprotein that lacks an intrinsic enzymatic domain and instead relies on the recruitment of TRAF proteins—specifically TRAF1, TRAF2, TRAF3, and TRAF5—to its cytoplasmic tail to initiate downstream signaling (UniProt P28908; PubMed 10438925). This interaction primarily activates the nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways, such as JNK and p38, which promote cell survival, proliferation, and anti-apoptotic signals (PubMed 10748121). In clinical contexts, CD30 is highly expressed in certain malignancies, such as Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL), where the constitutive TRAF-mediated signaling drives tumor progression (NCBI Gene ID 943). While current therapies like Brentuximab vedotin target the CD30 receptor itself for drug delivery, the specific TRAF–CD30 intracellular interaction represents an emerging target for small-molecule inhibitors designed to disrupt oncogenic signaling without affecting other TNFR family members (PubMed 21953159). Targeting this protein-protein interaction aims to block the survival signals in malignant cells by preventing the assembly of the signalosome at the receptor's cytoplasmic domain. Understanding this interaction is vital for developing more selective treatments for CD30-positive lymphoproliferative disorders and potentially certain autoimmune conditions.

Other names

CD30–TRAF signaling complexTNFRSF8–TRAF interactionCD30 cytoplasmic tail interactionCD30-TRAF2 interactionCD30-TRAF5 interaction

Inhibition of CD30-mediated pro-survival signaling by targeting the receptor for degradation or blocking the recruitment of TRAF adapter proteins to the intracellular domain, thereby preventing NF-kappaB and MAPK pathway activation.